Abstract Background and Aims Vedolizumab [VDZ] is a monoclonal antibody directed
against the α4β7 integrin heterodimer, approved for patients with inflammatory bowel …

Background Italian data currently available in managing ulcerative colitis (UC) and Crohn's
disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary …

Optimal management of inflammatory bowel disease (IBD) relies on a clear understanding
and tailoring evidence-based interventions by clinicians in partnership with patients. This …

To gain a better understanding of the effects of biologics, we evaluated clinical outcomes in
patients with moderate to severe exacerbations of ulcerative colitis (UC). This retrospective …

Background Deep remission (DR) is a treatment target in IBD associated with reduced
hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates …

There is increased risk of cardiovascular disease in patients with chronic inflammatory
disorders such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus …

Background This observational real‐world evidence (RWE) study is based on prospectively
collected data from the VEDOIBD registry study. Aim To compare the effectiveness of …

Background Data from real-life populations about vedolizumab as first-line biological
therapy for ulcerative colitis (UC) and Crohn's disease (CD) are emerging. Objective To …

Introduction Characterised by chronic inflammation of the gastrointestinal tract, inflammatory
bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can …

Background Blocking immune cell gut homing via α4β7 integrin with the monoclonal
antibody vedolizumab is an established therapeutic strategy in inflammatory bowel disease …